Icosavax Inc. is a biotechnology company that focuses on the development of vaccines against infectious diseases. It was founded in 2017 and is headquartered in Seattle, Washington. The company utilizes its innovative virus-like particle (VLP) platform technology to design and produce novel vaccines that target a range of viral pathogens.
The primary objective of Icosavax is to address significant unmet medical needs by creating safe and effective vaccines that can prevent or mitigate the impact of infectious diseases. The VLP technology allows the company to mimic the structure and characteristics of viruses, triggering an immune response without causing disease. This approach has shown promise in generating potent and durable immune responses in preclinical studies.
Icosavax's vaccine pipeline includes candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which are common causes of respiratory infections in infants, children, and the elderly. The company's goal is to develop vaccines that can provide long-lasting protection against these viral infections.
Icosavax has attracted significant attention and support from the biopharmaceutical industry and investors due to the potential impact of its vaccine platform. With its experienced leadership team and scientific expertise, the company is poised to make significant contributions to the field of infectious disease prevention. By leveraging its VLP technology, Icosavax aims to revolutionize vaccine development and improve global public health outcomes by addressing the challenges posed by viral infections.